SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

FibroGen, Inc. (FGEN)

FGEN RSS Feed
Add FGEN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 7/9/2016 8:12:21 AM - Followers: 19 - Board type: Free - Posts Today: 0
FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158
United States
Phone: 415-978-1200
Fax: 415-978-1902
Website: http://www.fibrogen.com

FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
FGEN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
FGEN News: Statement of Changes in Beneficial Ownership (4) 11/30/2016 06:41:11 PM
FGEN News: Statement of Changes in Beneficial Ownership (4) 11/18/2016 05:11:40 PM
FGEN News: Current Report Filing (8-k) 11/15/2016 05:19:02 PM
FGEN News: Quarterly Report (10-q) 11/08/2016 04:14:11 PM
FGEN News: Current Report Filing (8-k) 11/08/2016 04:06:59 PM